<DOC>
	<DOCNO>NCT00072033</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel cisplatin , use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving combination chemotherapy radiation therapy surgery may shrink tumor remove . PURPOSE : This phase II trial study well give docetaxel cisplatin together chemoradiotherapy follow surgery work treat patient locally advance , resectable esophageal cancer .</brief_summary>
	<brief_title>Neoadjuvant Docetaxel Cisplatin Plus Chemoradiotherapy Followed By Surgery Treating Patients With Locally Advanced , Resectable Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effectiveness neoadjuvant docetaxel cisplatin chemoradiotherapy follow surgery , term pathological response rate , patient locally advance , resectable esophageal cancer . - Determine feasibility regimen , term successful completion therapy survival 30 day postoperatively , patient . Secondary - Determine parameter disease control patient toxicity regimen compare parameter publish result . - Correlate early improvement dysphasia 1-2 course chemotherapy predictive value regard tumor response long-term disease control patient treat regimen . - Determine quality life patient treat regimen . - Determine clinical benefit regimen patient . OUTLINE : This multicenter study . - Neoadjuvant chemotherapy : Patients receive docetaxel IV 1 hour cisplatin IV 1 hour day 1 22 . - Chemoradiotherapy : Beginning 21 day last dose neoadjuvant chemotherapy , patient receive docetaxel IV 30 minute cisplatin IV 1 hour week undergo radiotherapy 5 day week 5 week . - Surgery : Patients undergo surgery 3-8 week final administration radiotherapy . Treatment continue absence disease progression unacceptable toxicity . Quality life assess baseline , day 22 chemotherapy , day 1 chemoradiotherapy , surgery , every 3 month 1 year . Patients follow every 3 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 22-66 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma adenocarcinoma thoracic esophagus , include gastroesophageal junction ( Siewert type I ) Locally advanced disease technically operable curative intent ( R0 ) T3 , N0 OR T13 , N+ OR T4 , NX No T12 , N0 No inoperable T4 ( unequivocal organ involvement ) No distant metastasis , include M1a lymph node status Lymph nod suspicious M1a status CT scan , PET scan , ultrasound must verify fineneedle aspiration cytology No carcinoma cervical esophagus Obstructive tumor allow PATIENT CHARACTERISTICS : Age 18 70 Performance status WHO 01 Life expectancy Not specify Hematopoietic Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic AST great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Bilirubin great 1.5 time ULN Renal Creatinine clearance great 60 mL/min Cardiovascular No New York Heart Association class III IV congestive heart failure No unstable angina pectoris No myocardial infarction within past 3 month No significant arrhythmias No severe uncontrolled cardiovascular disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month study treatment No definite contraindication corticosteroid premedication No geographic situation would preclude proper stag followup No active uncontrolled infection No preexist peripheral neuropathy great grade 1 No uncontrolled diabetes mellitus No active autoimmune disease No serious medical condition would preclude study participation No prior concurrent malignancy except nonmelanoma skin cancer adequately treat carcinoma situ cervix No significant neurologic psychiatric disorder , include psychotic disorder , dementia , seizure would preclude comprehension ability provide inform consent complete quality life questionnaires PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy chest Surgery Not specify Other More 30 day since prior treatment another clinical trial No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
</DOC>